What are the costs of heart failure?

Europace

Volumn 13, Issue SUPPL. 2, 2011, Pages

  Braunschweig, Frieder ^a   Cowie, Martin R ^b   Auricchio, Angelo ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c DIVISION OF CARDIOLOGY   (Switzerland)

Author keywords

Cost; Cost effectiveness; Heart failure; Hospitalization

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; ARTIFICIAL HEART PACEMAKER; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH PROGRAM; HEART FAILURE; HOSPITAL CARE; HOSPITALIZATION; HUMAN; OUTPATIENT; PRIORITY JOURNAL;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; EUROPE; HEALTH CARE COSTS; HEART FAILURE; HOSPITALIZATION; HUMANS; PREVALENCE; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 79955587610     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur081     Document Type: Article

References (44)

1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC et al. The epidemiology of heart failure. Eur Heart J 1997;18:208-25. (Pubitemid 27107582)
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
4. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010;121:e46-215.
5. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J et al. 2010 Focused Update of ESC guidelines on device therapy in heart failure: An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010;12:1143-53.
6. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126-31.
7. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A.ecreasing one-year mortality and hospitalization rates for heart failure in Sweden; data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 2004; 25:300-7. (Pubitemid 38295438)
8. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More xmalignant' than cancerfi Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-22. (Pubitemid 32895839)
9. Meerding WJ, Bonneux L, Polder JJ, Koopmanschap MA, van der Maas PJ. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ 1998;317:111-5. (Pubitemid 28310617)
10. Rodriguez-Artalejo F, Guallar-Castillon P, Banegas Banegas JR, del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J 1997;18:1771-9. (Pubitemid 27477928)
11. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24:442-63. (Pubitemid 36286187)
12. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics 2008;26:447-62. (Pubitemid 351704856)
13. National Clinical Guideline Centre. The Management of Chronic Heart Failure in Adults in Primary and Secondary Care, 2010. http://guidance.nice.org. uk/CG108/Guidance/pdf/English.
14. Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001;161: 1183-92. (Pubitemid 32691515)
15. Rydén-Bergsten T, Andersson F. The health care costs of heart failure in Sweden. J Intern Med 1999;246:275-84. (Pubitemid 29426446)
16. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361-71. (Pubitemid 35190362)
17. Levy E. From cost of illness to cost-effectiveness in heart failure. Eur Heart J 1998; 19(Suppl. P):2-4.
18. Cope JT, Kaza AK, Reade CC, Shockey KS, Kern JA, Tribble CG et al. A cost comparison of heart transplantation versus alternative operations for cardiomyopathy. Ann Thorac Surg 2001;72:1298-305. (Pubitemid 32938023)
19. Clegg AJ, Scott DA, Loveman E, Colquitt J, Hutchinson J, Royle P et al. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation. Health Technol Assess 2005;9:1-132, iii-iv.
20. Hernandez AF, Shea AM, Milano CA, Rogers JG, Hammill BG, O'Connor CM et al. Long-term outcomes and costs of ventricular assist devices among medicare beneficiaries. JAMA 2008;300:2398-406.
21. Stewart S. Financial aspects of heart failure programs of care. Eur J Heart Fail 2005; 7:423-8. (Pubitemid 40249534)
22. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(Suppl. 7):S21-30. (Pubitemid 37526952)
23. O'Connor CM, Fiuzat M. Is rehospitalization after heart failure admission a marker of poor qualityfi Time for re-evaluation. J Am Coll Cardiol 2010;56:369-71.
24. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005;11:200-5. (Pubitemid 40462423)
25. Cowie MR, Fox KF, Wood DA, Metcalfe C, Thompson SG, Coats AJ et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002;23:877-85. (Pubitemid 34717423)
26. Whellan DJ, Greiner MA, Schulman KA, Curtis LH. Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. Circ Cardiovasc Qual Outcomes 2010;3:33-40.
27. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
28. Whellan DJ, Hasselblad V, Peterson E, O'Connor CM, Schulman KA. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J 2005;149:722-9.
29. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 2008;168:316-24. (Pubitemid 351281679)
30. Clark RA, Inglis SC, McAlister FA, Cleland JG, Stewart S. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ 2007;334:942.
31. Klersy C, De Silvestri A, Gabutti G, Regoli F, Auricchio A. A meta-analysis of remote monitoring of heart failure patients. J Am Coll Cardiol 2009;54:1683-94.
32. Klersy C, De Silvestri A, Gabutti G, Raisaro A, Moreno C, Regoli F et al. Economic impact of remote patient monitoring. An integrated economic model derived from a metaanalysis of randomized controlled trials in heart failure. Eur J Heart Fail; Published online ahead of print 11 February, 2011.
33. Ekman M, Zethraeus N, Jonsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics 2001;19:901-16. (Pubitemid 32937941)
34. McMurray JJ, Andersson FL, Stewart S, Svensson K, Solal AC, Dietz R et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006;27:1447-58. (Pubitemid 43998079)
35. Paul SD, Kuntz KM, Eagle KA,Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154:1143-9. (Pubitemid 24155213)
36. Szucs TD, Holm MV, Schwenkglenks M, Zhang Z,WeintraubWS, Burnier M et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction - an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther 2006;20:193-204. (Pubitemid 44099817)
37. Caro JJ, Migliaccio-Walle K, O'Brien JA, Nova W, Kim J, Hauch O et al. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. J Card Fail 2005;11: 647-56. (Pubitemid 41797492)
38. Glick HA, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther 2002;16:53-9. (Pubitemid 34606612)
39. Stewart S, McMurray JJ, Hebborn A, Coats AJ, Packer M. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. Int J Cardiol 2005;100:143-9. (Pubitemid 40487948)
40. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet 2010;376:875-85.
41. Topol EJ. Nesiritide - not verified. N Engl J Med 2005;353:113-6. (Pubitemid 41058341)
42. Cleland JG, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe lowoutput heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003;5:101-8. (Pubitemid 36205551)
43. Groeneveld PW, Epstein AJ, Yang F, Yang L, Polsky D. Increasing Use of Cardiovascular Devices and Rising Health Care Costs Quality of care and outcomes research in cardiovascular disease and stroke, 2010 scientific sessions, Washington DC 2010;17, abstract.
44. Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, Piepoli M, Francis DP. Life-years gained from defibrillator implantation: markedly nonlinear increase during 3 years of follow-up and its implications. Circulation 2004;109:1848-53. (Pubitemid 38509118)